Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | LSS | P48449 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18306897 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2BACE1BACE2SSTR4GABRA1 | |
| SCHEMBL15672525 | 0.87 | SMN1; SMN2 (0.36) | SMN1; SMN2BACE1BACE2SSTR4GABRA1 | |
| SCHEMBL15672498 | 0.87 | SMN1; SMN2 (0.38) | SMN1; SMN2BACE1BACE2SSTR4GABRA1 | |
| SCHEMBL15662249 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2 | |
| SCHEMBL15662250 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2 | |
| SCHEMBL15661870 | 0.81 | KDM4E (0.33) | SMN1; SMN2SSTR4 | |
| SCHEMBL15661869 | 0.81 | KDM4E (0.33) | SMN1; SMN2SSTR4 | |
| SCHEMBL15282543 | 0.77 | TSHR (0.38) | SMN1; SMN2HDAC1LSS | |
| SCHEMBL15282544 | 0.77 | TSHR (0.38) | SMN1; SMN2HDAC1LSS | |
| SCHEMBL15672541 | 0.76 | RAB9A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328124-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328124-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150232483-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY | 2015-08-20 | — | — | US | disclosed |
| US-20150232483-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232483-A1 | BACE INHIBITORS | BACE1, BACE2, APP | SMN1; SMN2 1298/4885BACE1 1/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.